Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy.
IL-1 receptor antagonist
IL-1β
anakinra
cytokine
febrile infection-related epilepsy syndrome
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
received:
22
05
2021
revised:
09
06
2021
accepted:
10
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
15
7
2021
Statut:
epublish
Résumé
Febrile Infection-Related Epilepsy Syndrome (FIRES) is a unique catastrophic epilepsy syndrome, and the development of drug-resistant epilepsy (DRE) is inevitable. Recently, anakinra, an interleukin-1 receptor antagonist (IL-1RA), has been increasingly used to treat DRE due to its potent anticonvulsant activity. We here summarized its effects in 38 patients (32 patients with FIRES and six with DRE). Of the 22 patients with FIRES, 16 (73%) had at least short-term seizure control 1 week after starting anakinra, while the remaining six suspected anakinra-refractory cases were male and had poor prognoses. Due to the small sample size, an explanation for anakinra refractoriness was not evident. In all DRE patients, seizures disappeared or improved, and cognitive function improved in five of the six patients following treatment. Patients showed no serious side effects, although drug reactions with eosinophilia and systemic symptoms, cytopenia, and infections were observed. Thus, anakinra has led to a marked improvement in some cases, and functional deficiency of IL-1RA was indicated, supporting a direct mechanism for its therapeutic effect. This review first discusses the effectiveness of anakinra for intractable epileptic syndromes. Anakinra could become a new tool for intractable epilepsy treatment. However, it does not currently have a solid evidence base.
Identifiants
pubmed: 34208064
pii: ijms22126282
doi: 10.3390/ijms22126282
pmc: PMC8230637
pii:
doi:
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Epilepsy Research Foundation
ID : 20012
Références
Neuropediatrics. 2017 Feb;48(1):5-18
pubmed: 27919115
Neurosci Lett. 2011 Jun 27;497(3):223-30
pubmed: 21362451
J Neuroimmunol. 2021 Mar 15;352:577475
pubmed: 33454554
Ann Clin Transl Neurol. 2020 Dec;7(12):2467-2474
pubmed: 33506622
Epilepsia. 2018 Apr;59(4):e45-e50
pubmed: 29512885
Epilepsia. 2011 Nov;52(11):1956-65
pubmed: 21883180
Epilepsia. 2018 Apr;59(4):739-744
pubmed: 29399791
Epilepsia. 2010 Jun;51(6):1069-77
pubmed: 19889013
Ann Rheum Dis. 2007 May;66(5):589-98
pubmed: 17170049
J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):820-2
pubmed: 25398790
Ann Neurol. 2018 Dec;84(6):940-945
pubmed: 30408233
Epilepsy Behav Rep. 2021 Feb 04;15:100431
pubmed: 33748736
Lancet Neurol. 2016 Sep;15(10):1075-88
pubmed: 27571159
Epilepsia Open. 2021 Jan 13;6(1):62-72
pubmed: 33681649
J Neuroinflammation. 2017 Oct 10;14(1):200
pubmed: 29017522
Epilepsy Behav. 2015 Jun;47:17-23
pubmed: 26010959
Epilepsy Behav Rep. 2020 Jul 03;14:100379
pubmed: 32995738
Epilepsia. 2013 May;54 Suppl 2:23-8
pubmed: 23646967
J Pathol. 2017 Jul;242(3):284-296
pubmed: 28378341
J Neurosci. 2010 Jun 2;30(22):7484-94
pubmed: 20519523
Ann Neurol. 2019 Apr;85(4):526-537
pubmed: 30779222
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11534-9
pubmed: 11016948
J Neurochem. 2008 Jul;106(1):271-80
pubmed: 18384650
Nat Rev Neurol. 2011 Jan;7(1):31-40
pubmed: 21135885
J Neurol Sci. 2010 Nov 15;298(1-2):106-9
pubmed: 20807663
J Child Neurol. 2018 Jul;33(8):528-533
pubmed: 29724126
Cytokine Growth Factor Rev. 2011 Aug;22(4):189-95
pubmed: 22019906
Child Neurol Open. 2020 Dec 15;7:2329048X20979253
pubmed: 33403221
J Neurol Sci. 2016 Sep 15;368:272-6
pubmed: 27538648
Hum Vaccin Immunother. 2014;10(4):868-75
pubmed: 24609096
WMJ. 2019 Oct;118(3):135-139
pubmed: 31682750
Neurobiol Dis. 2017 Mar;99:12-23
pubmed: 27939857
Int J Legal Med. 2016 Mar;130(2):331-9
pubmed: 26423924
J Neuroinflammation. 2018 Feb 09;15(1):38
pubmed: 29426321
Orphanet J Rare Dis. 2019 May 3;14(1):96
pubmed: 31053163
Int J Legal Med. 2015 May;129(3):495-504
pubmed: 25119684
Neurosci Biobehav Rev. 2016 Apr;63:177-90
pubmed: 26877106
Exp Neurol. 2013 Jun;244:11-21
pubmed: 21985866
Neuroimmunomodulation. 2010;17(1):19-22
pubmed: 19816053
J Neurosci. 2013 Dec 11;33(50):19579-89
pubmed: 24336722
Brain Behav Immun. 2008 Aug;22(6):797-803
pubmed: 18495419
Epilepsia. 2018 Apr;59(4):745-752
pubmed: 29476535
Ann Indian Acad Neurol. 2016 Apr-Jun;19(2):188-94
pubmed: 27293328
Neuropathol Appl Neurobiol. 2018 Feb;44(1):91-111
pubmed: 28977690
Epilepsia. 2011 May;52 Suppl 3:26-32
pubmed: 21542843
Sci Rep. 2016 Feb 23;6:21931
pubmed: 26902320
J Child Neurol. 2017 Jan;32(1):35-40
pubmed: 27655472
Epilepsia. 2002 Aug;43(8):920-3
pubmed: 12181012
Epilepsia. 2017 Jun;58(6):1102-1111
pubmed: 28448686
Pediatr Neurol. 2021 Jan;114:60-61
pubmed: 33227629
Epilepsia. 2019 Aug;60(8):1678-1688
pubmed: 31283843
Eur J Paediatr Neurol. 2019 Sep;23(5):749-754
pubmed: 31446001
Nat Rev Drug Discov. 2012 Aug;11(8):633-52
pubmed: 22850787
BMC Neurol. 2020 Mar 9;20(1):85
pubmed: 32151248
Rheumatology (Oxford). 2019 Nov 1;58(Suppl 6):vi9-vi22
pubmed: 31769856
Seizure. 2013 Sep;22(7):553-9
pubmed: 23643626
Nat Rev Neurol. 2019 Aug;15(8):459-472
pubmed: 31263255
Lancet Neurol. 2011 Jan;10(1):99-108
pubmed: 21163447
Epilepsia Open. 2019 Mar 27;4(2):344-350
pubmed: 31168503
J Neuroimmunol. 2020 Mar 15;340:577142
pubmed: 31935626
Acta Neurol Scand. 2007 Oct;116(4):226-30
pubmed: 17824899
J Neurosci. 1999 Jun 15;19(12):5054-65
pubmed: 10366638
J Neurol Sci. 2009 May 15;280(1-2):94-7
pubmed: 19272615
Neurosci Bull. 2016 Oct;32(5):481-92
pubmed: 27562688
Orphanet J Rare Dis. 2016 Nov 3;11(1):145
pubmed: 27809914
Ann Neurol. 2016 Dec;80(6):939-945
pubmed: 27770579
Epileptic Disord. 2020 Apr 1;22(2):183-193
pubmed: 32301731